This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response
rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy
with either KTd or KRd followed by randomization to either carfilzomib maintenance treatment
for 12 months or to observation only. Maintenance is given for 12 cycles or progression of
disease, whatever occurs first.